Is CTMX or CVKD more undervalued in 2026?

CirclFi compares CytomX Therapeutics, Inc. (CTMX) and Cadrenal Therapeutics, Inc. (CVKD) using 13 institutional-grade valuation models. CTMX has a Quality of Company score of 6.7/10 while CVKD scores 4.7/10.

Which is a better buy — CTMX or CVKD?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do CTMX and CVKD valuations compare?

CTMX at $3.71 and CVKD at $5.00 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

CTMX vs CVKD Valuation Comparison 2026 — Intrinsic Value Analysis

CTMX

Biotechnology

CytomX Therapeutics, Inc.

Quality

6.7

out of 10

Value Trap

SAFE

Price

$3.71

Last close

Models

12/13

Active

CVKD

Biotechnology

Cadrenal Therapeutics, Inc.

Quality

4.7

out of 10

Value Trap

—

Price

$5.00

Last close

Models

7/13

Active

Model-by-Model Comparison

Model	Type	CTMX Fair Value	CTMX Upside	CVKD Fair Value	CVKD Upside
Bayesian DCF	Intrinsic	$0.80	-78.4%	$1.40	-72.0%
Earnings Power Value	Intrinsic	$0.37	-90.8%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$1.28	-65.5%	$1.16	-76.9%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for CTMX vs CVKD — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CTMX vs CVKD — Which Stock Is More Undervalued?

CTMX scores higher with a 6.7/10 quality rating vs CVKD's 4.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing CytomX Therapeutics, Inc. (CTMX) and Cadrenal Therapeutics, Inc. (CVKD) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CTMX currently trades at $3.71 with a QOC of 6.7/10, while CVKD trades at $5.00 with a QOC of 4.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).